R
Receptos
Focuses on the discovery, development and commercialization of various therapeutics for immune disorders
About Receptos
Receptos, a subsidiary of Celgene and part of Bristol Myers Squibb, specializes in developing innovative therapies for complex diseases such as multiple sclerosis, acute myeloid leukemia, and multiple myeloma. The company operates in the biopharmaceutical sector, serving patients, healthcare providers, and medical professionals. Receptos focuses on research and development, leveraging scientific advancements to create effective treatments. The business model revolves around the development, approval, and commercialization of novel drugs, generating revenue through product sales and partnerships. The company is committed to patient safety, advocacy, and support, ensuring that their therapies not only meet regulatory standards but also improve patient outcomes. Receptos collaborates with various stakeholders, including European patient organizations and medical institutions, to enhance its research capabilities and expand its market reach. The company also offers grants for scientific advancement and independent medical education, further contributing to the medical community. Key areas of focus include drug safety, risk management, and clinical trials, ensuring that their products are both safe and effective. Receptos' commitment to corporate responsibility and ethical conduct underscores its dedication to making a positive impact on global health.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- San Diego, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 60.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2015 | $7.3B | — | Celgene | — |
| IPO✓Exit | May 2013 | $0 | — | Lilly Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Receptos is 0 monthly website visits. Receptos's team declined 18.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Venrock
Lilly Ventures
OrbiMed
ARCH Venture Partners
Osage University Partners
Flagship Pioneering
Polaris Partners
Altitude Life Science Ventures
Other known investors2 additional known investors
Celgene
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Receptos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Receptos’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.